Maserati R, Mussati G, Scudeller L, Chiapparoli L, Giacchino R, Zanaboni D; International Conference on AIDS.
Int Conf AIDS. 1998; 12: 1149 (abstract no. 60808).
Infect Dis Dept-Policlinico San Matteo, Pavia, Italy.
BACKGROUND: Among pts treated with IDV, an increase of indirect bilirubin is reported in around 15% of cases. We studied the clinical relevance of this event in our population of HIV-infected pts treated with combo therapies containing IDV. METHODS: Seventy-eight pts started a combo anti-HIV therapy containing IDV from October '96 through December '97. Demographic factors, CDC '93 classification, HBV and HCV coinfection, associated drugs (in particular nRTIs) and biochemical values were evaluated. Blood tests (namely total and indirect bilirubin) were performed monthly during therapy. Two groups of pts were identified: group 1 (pts who showed an increase of bilirubin levels above normal value of 1 mg/dL during therapy) and group 2 (pts who did not). RESULTS: Forty-three out of 78 (55.1%) pts showed an increase of bilirubin levels with a mean peak time of 4 months (range 1-8) and a mean peak value of 2.39 mg/dL (range 1.01-4.95). While most pts remained hyperbilirubinemic, among the 14 who have so far reached the 12th month of therapy, 6 (43%) show normal biliribin levels. No difference was seen between the two groups in sex, age, risk factor, CDC classification, coinfections with HBV and HCV, nRTIs associated. Group 2 had a significant lower mean duration of therapy than group 1 (4.1 vs 8.3 months; p < 0.001). CONCLUSIONS: Bilirubin increase is a negligible and possibly reversible effect of IDV administration and it doesn't cause a significant liver toxicity or any other clinically relevant adverse event. The decision to discontinue IDV should not be based merely upon the occurrence of hyperbilirubinemia.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- HIV Infections
- HIV Seropositivity
- Humans
- Hyperbilirubinemia
- Indinavir
Other ID:
UI: 102232755
From Meeting Abstracts